Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Katrina PiedraTim PetersonCarlyn TanJennifer OrozcoMalin HultcrantzHani HassounSham MailankodyAlexander LesokhinUrvi ShahSydney LuDhwani PatelAndriy DerkachCy R WilkinsNeha KordePublished in: British journal of haematology (2021)
Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates.
Keyphrases
- venous thromboembolism
- multiple myeloma
- newly diagnosed
- direct oral anticoagulants
- low dose
- high dose
- end stage renal disease
- ejection fraction
- atrial fibrillation
- gene expression
- type diabetes
- machine learning
- peritoneal dialysis
- coronary artery disease
- stem cell transplantation
- cardiovascular disease
- single cell
- pulmonary embolism
- data analysis
- deep learning